Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote
This article was originally published in RPM Report
Executive Summary
Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.
You may also be interested in...
Advocacy For Drug Safety And Public Health Loses Passionate And Effective Leader Sidney Wolfe
Wolfe is lauded by former colleagues for his fierceness in pushing to get dangerous drugs off the market, his rigorous scientific approach, and mastery of the press.
Sidney Wolfe, Iconic Advocate For Drug Safety, Dies At 86
Wolfe is lauded by former colleagues for his fierceness in pushing to get dangerous drugs off the market, his rigorous scientific approach, and mastery of the press.
“Do Not Compound” List One Step Closer, After FDA Names Advisors
FDA’s pharmacy compounding efforts in 2015 should include additional guidance and work by an advisory committee to build a “do-not-compound” list.